Convelo Therapeutics Inc. and Genentech Inc. have identified lanosterol 14α-demethylase (CYP51A1; CYP51) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Kinnate Biopharma Inc. has synthesized mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.

Arrepath Inc. has disclosed UDP-2,3-diacylglucosamine hydrolase (LpxH; bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.

Filamon Pty. Ltd. has described lysosomal targeting peptides (LYTAPs) acting as EGFR (HER1; erbB1) degradation inducers reported to be useful for the treatment of cancer.

Apellis Pharmaceuticals Inc. has divulged complement C3 inhibitors reported to be useful for the treatment of hemolytic anemia.

Baoyuan Biomedical Technology (Hangzhou) Co. Ltd. has identified serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of cancer.

JW Pharmaceutical Corp. has synthesized heterocyclic derivatives reported to be useful for the treatment of atopic dermatitis or pruritus.

Arcus Biosciences Inc. has disclosed mast/stem cell growth factor receptor Kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, allergy, autoimmune, inflammatory, cardiovascular, metabolic, dermatological and respiratory disorders, among others.

Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have presented NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.

Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.